GoodRx Holdings, Inc. - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. GoodRx operates a digital healthcare platform providing prescription price comparison, savings codes, subscription programs, and direct-to-consumer solutions for pharmaceutical manufacturers (Pharma Direct). The company is navigating a shifting retail pharmacy landscape, including store closures and the emergence of government-sponsored platforms like "TrumpRx.gov."
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $194.0 million | $203.0 million |
| Net Income | $1.2 million | $11.1 million |
| Net Income Margin | 0.6% | 5.4% |
| Adjusted EBITDA | $58.3 million | $69.8 million |
| Adjusted EBITDA Margin | 30.0% | 34.4% |
| Cash and Cash Equivalents | $235.7 million | $301.0 million |
| Debt (Net) | $487.4 million | $488.3 million |
| Operating Cash Flow | $11.8 million | $9.4 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 4% year-over-year (YoY). Prescription transactions revenue dropped 24% to $113.7 million due to reduced Monthly Active Consumers (5.3 million vs. 6.4 million) driven by retail pharmacy store closures and volume reductions in integrated savings programs.
- Pharma Direct Growth: Pharma Direct revenue surged 82% to $52.2 million, driven by expanded market penetration and consumer direct pricing initiatives.
- Subscription Growth: Subscription revenue increased 16% to $24.4 million, with total subscription plans rising to 717,000.
- Profitability Compression: Net income margin contracted from 5.4% to 0.6% due to lower revenue and higher cost of revenue (up 51% YoY) related to new acquisitions and fulfillment costs.
- Balance Sheet Shifts: Prescription reimbursement assets increased significantly to $753.5 million (from $98.3 million), while corresponding liabilities rose to $751.0 million, reflecting changes in the timing of deposits and reimbursements within the Pharma Direct model.
Outlook, Risks, and Management Commentary
- Strategic Pivot: Management is shifting focus toward Pharma Direct and subscription offerings to offset headwinds in the traditional prescription transactions model. They anticipate near-term impacts on unit economics as they scale these new verticals.
- Market Dynamics: The company notes the impact of the "TrumpRx.gov" platform, launched in February 2026. GoodRx is an integration partner; initial data suggests incremental demand rather than displacement of existing users.
- Legal Contingencies: A consumer privacy class action settlement of $25.0 million is accrued but pending final court approval. Additional state-level litigation regarding discount card compliance remains ongoing in Arkansas and Minnesota.
- Liquidity: The company maintains $235.7 million in cash and $80.4 million available under its revolving credit facility. It continues a stock repurchase program with $60.2 million remaining available.
Investor Verification Checklist
- Pharma Direct Sustainability: Verify the durability of the 82% revenue growth in Pharma Direct and whether it can fully offset the decline in core prescription transactions.
- Legal Resolution: Monitor the status of the $25.0 million privacy class action settlement and potential outcomes of state-level discount card litigation.
- Consumer Metrics: Track the stabilization of Monthly Active Consumers (down to 5.3 million) and the conversion rate to subscription plans.
- Balance Sheet Volatility: Review the significant increase in prescription reimbursement assets and liabilities to understand cash flow timing risks.
- Competitive Landscape: Assess the long-term impact of the "TrumpRx.gov" platform and retail pharmacy consolidations on GoodRx's pricing power.